Deficiency of CFHR plasma proteins and autoantibody positive hemolytic uremic syndrome: treatment rationale, outcomes, and monitoring

Pediatr Nephrol. 2021 Jun;36(6):1365-1375. doi: 10.1007/s00467-020-04652-x. Epub 2020 Jun 12.

Abstract

Deficiency of Complement Factor H Related (CFHR) plasma proteins and Autoantibody Positive Hemolytic Uremic Syndrome (DEAP-HUS) is a subtype of atypical hemolytic uremic syndrome, known to be associated with significant morbidity. Its pathogenesis is linked to the production of IgG autoantibodies against complement factor H, a regulator of the alternative complement pathway. The binding of the autoantibodies to the C terminal of complement factor H interferes with its regulatory function, leading to increased activation of the alternative complement pathway and consequent endothelial cellular damage. Early diagnosis and initiation of appropriate therapy is reported to lead to favorable outcomes. Institution of plasma exchange therapy within 24 h of diagnosis has been shown to rapidly lower antibody levels, leading to clinical improvement. Adjunctive immunosuppression therapy suppresses antibody production and helps in maintaining long-term clinical remission of the disease. Available data advocates a treatment regimen that combines plasma therapy (preferably plasma exchange) and immunosuppression to halt disease process and sustain long-term disease remission.

Keywords: Alternative complement pathway; Complement activation; DEAP-HUS; Hemolytic uremic syndrome.

Publication types

  • Review

MeSH terms

  • Atypical Hemolytic Uremic Syndrome* / diagnosis
  • Atypical Hemolytic Uremic Syndrome* / therapy
  • Autoantibodies*
  • Complement Factor H* / deficiency
  • Humans
  • Immunosuppression Therapy
  • Plasma Exchange

Substances

  • Autoantibodies
  • Complement Factor H